EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Aqueous VEGF-A Levels as a Liquid Biopsy Biomarker of Retinoblastoma Vitreous Seed Response to Therapy

Anthony B Daniels, Kamakshi L Sishtla, Carley M Bogan, Janene M Pierce, Sheau-Chiann Chen, Liya Xu, Jesse L Berry, Timothy W Corson

Investigative Ophthalmology & Visual Science · 2024

DOI: 10.1167/iovs.65.6.18 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2024. Written by Anthony B Daniels and 7 co-authors. Institution: Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, and Department of Radiation Oncology, Vanderbilt Eye Inst…. Major MEDLINE topics: Retinoblastoma, Retinal Neoplasms, Vascular Endothelial Growth Factor A, Aqueous Humor. Cited 7 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, NEI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

Regression of retinoblastoma vitreous seeds (VS) during intravitreal chemotherapy can be delayed, resulting in supernumerary injections. Similarly, VS relapse may not be clinically evident at first. A predictive biomarker of tumor regression and relapse could help guide real-time clinical decision making. Retinoblastoma is an oxygen-sensitive tumor; paradoxically, VS survive in the hypoxic vitreous. We hypothesized that VS elaborate pro-angiogenic cytokines. The purpose was to determine if pro-angiogenic cytokine signatures from aqueous humor could serve as a biomarker of VS response to treatment.

Methods

Multiplex ELISA was performed on aqueous from rabbit eyes with human retinoblastoma VS xenografts to identify expressed proangiogenic cytokines and changes in aqueous cytokine levels during intravitreal treatment were determined. Confirmatory RNAscope in situ hybridization for VEGF-A was performed on human retinoblastoma tumor sections and VS xenografts from rabbits. For human eyes undergoing intravitreal chemotherapy, serial aqueous VEGF-A levels measured via VEGF-A-specific ELISA were compared to clinical response.

Results

VEGF-A was highly expressed in human retinoblastoma VS in the xenograft model, and was the only proangiogenic cytokine that correlated with VS disease burden. In rabbits, aqueous VEGF-A levels decreased in response to therapy, consistent with quantitative VS reduction. In patients, aqueous VEGF-A levels associated with clinical changes in disease burden (regression, stability, or relapse), with changes in VEGF-A levels correlating with clinical response.

Conclusions

Aqueous VEGF-A levels correlate with extent of retinoblastoma VS, suggesting that aqueous VEGF-A may serve as a predictive molecular biomarker of treatment response.

Subjects

MeSH terms (MEDLINE)

RetinoblastomaRetinal NeoplasmsVascular Endothelial Growth Factor AAqueous HumorVitreous BodyBiomarkers, TumorEnzyme-Linked Immunosorbent AssayIntravitreal InjectionsAnimalsHumansRabbitsLiquid BiopsyNeoplasm SeedingFemaleAngiogenesis InhibitorsCytokines

Substances

Vascular Endothelial Growth Factor ABiomarkers, TumorVEGFA protein, humanAngiogenesis InhibitorsCytokines

Authors and institutions

  • Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, and Department of Radiation Oncology, Vanderbilt Eye Institute and Vanderbilt Ingram Cancer Center, Vanderbilt University Medic…
  • Department of Pharmacology and Toxicology, Department of Ophthalmology, Department of Biochemistry and Molecular Biology, and Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Ind…
  • Center for Quantitative Sciences, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
  • Children's Hospital - Los Angeles, University of Southern California, Los Angeles, California, United States.

Funding

  • NCI NIH HHS
  • NEI NIH HHS

Cite

APA

Daniels, A. B., Sishtla, K. L., Bogan, C. M., Pierce, J. M., Chen, S. C., Xu, L., Berry, J. L., & Corson, T. W. (2024). Aqueous VEGF-A Levels as a Liquid Biopsy Biomarker of Retinoblastoma Vitreous Seed Response to Therapy. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.65.6.18

Vancouver

Daniels AB, Sishtla KL, Bogan CM, Pierce JM, Chen SC, Xu L, et al. Aqueous VEGF-A Levels as a Liquid Biopsy Biomarker of Retinoblastoma Vitreous Seed Response to Therapy. Investigative Ophthalmology & Visual Science. 2024. doi:10.1167/iovs.65.6.18

BibTeX
@article{Daniels2024,
  author = {Daniels, Anthony B and Sishtla, Kamakshi L and Bogan, Carley M and Pierce, Janene M and Chen, Sheau-Chiann and Xu, Liya and Berry, Jesse L and Corson, Timothy W},
  title = {Aqueous VEGF-A Levels as a Liquid Biopsy Biomarker of Retinoblastoma Vitreous Seed Response to Therapy},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2024},
  doi = {10.1167/iovs.65.6.18}
}
Start for free →